Tezepelumab
Tezepelumab is a biologic medication classified as a thymic stromal lymphopoietin (TSLP) blocker. It is a human monoclonal antibody that binds to TSLP, a cytokine produced by epithelial cells, thereby preventing TSLP from triggering inflammatory responses in the airways. This medication is used as add-on maintenance therapy for patients with severe asthma.
Tezepelumab is a monoclonal antibody that blocks TSLP to reduce airway inflammation in patients with severe asthma.
Key facts at a glance
- ATC
- R03DX11
- RxNorm
- 2587789
- Generic
- Tezepelumab
- Class
- atc-r03
- Brands
- Tezspire
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 210mg
- Maximum
- consult physician
- Frequency
- every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 210mg
- Maximum
- consult physician
- Frequency
- every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 210mg
- Maximum
- consult physician
- Frequency
- every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if potential benefit justifies potential risk to fetus; discuss with healthcare provider
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second third trimestercontinue if already receiving therapy
do not discontinue asthma treatment; continue therapy if benefits outweigh risks
routine prenatal care and fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
continue if needed; monitor infant for infections
observe infant for unusual infections or immune reactions
Use with caution and monitor for adverse effects.
pediatric_age
under 12 yearsnot recommended
not approved for use in children under 12 years
N/A
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
12 to 17 yearsno adjustment needed
approved for use in patients 12 years and older; standard dosing applies
routine asthma monitoring
geriatric
65 years and olderno adjustment needed
use standard dosing; monitor for infections
regular assessment of asthma control and infection risk
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno adjustment needed
standard dosing recommended; monitor as appropriate
routine renal function monitoring not required
renal_impairment
severeno adjustment needed
use standard dosing with caution
routine monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno adjustment needed
use standard dosing; limited data available
routine liver function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with caution
use only if benefits outweigh risks; limited data available
close monitoring of liver function
Statistics and clinical data
FDA approval year
FDA approval for severe asthma
Drug class
Monoclonal antibody targeting thymic stromal lymphopoietin
Indication
Approved for treatment of severe asthma
Mechanism of action
Inhibits thymic stromal lymphopoietin to reduce airway inflammation
Tezepelumab is indicated as add-on maintenance treatment for adult and pediatric patients (12 years and older) with severe asthma who are inadequately controlled with standard asthma therapies.
Tezepelumab is a human monoclonal antibody (IgG2λ) that binds with high affinity to thymic stromal lymphopoietin (TSLP), blocking its interaction with the TSLP receptor complex. By inhibiting TSLP, it prevents the downstream activation of inflammatory cells that contribute to airway inflammation, hyperresponsiveness, and mucus production in asthma.
Tezepelumab is administered as a subcutaneous injection and is not indicated for acute asthma attacks or bronchospasm relief. Common side effects may include pharyngitis, arthralgia, and injection site reactions. Patients should be monitored for hypersensitivity reactions during treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy